L19-IL-2 is specific for the angiogenesis-associated B-FN isoform selectively accumulated on tumor neovasculature; L19-IL-2 showed a good anti-tumor activity in preclinical models both in solid and hematological tumors (Table 1). This evidence concerns the gene IL2 and neoplasm.